Azitra
AZTRAzitra Inc is an early-stage clinical biopharmaceutical company specializing in precision dermatology through the development of engineered proteins and topical live biotherapeutic products.
Table of contents
Earnings
Next report
Aug 10, 2026 (In 4 weeks)Competitors
By market cap
Profile
Azitra Inc is an early-stage clinical biopharmaceutical company specializing in precision dermatology through the development of engineered proteins and topical live biotherapeutic products. The company leverages a proprietary platform featuring a microbial library of approximately 1,500 bacterial strains and artificial intelligence to identify and engineer therapeutic candidates for chronic and rare skin diseases.
A pioneer in genetically engineering bacteria for dermatological use, utilizing a proprietary microbial library and AI-driven screening technologies.
Questions, answered.
- What is Azitra's market cap?
- Azitra (AZTR) has a market capitalization of $2.4M and trades on AMEX.
- Who are Azitra's competitors?
- Azitra's key competitors include Seres Therapeutics, Kymera Therapeutics, Inc. Common Stock, Turn Therapeutics Inc. Common Stock, and others. These companies compete in similar markets and product categories.
- Who does Azitra partner with?
- Azitra's notable partners include Carnegie Mellon University, Fred Hutchinson Cancer Center.
- Where is Azitra headquartered?
- Azitra is headquartered in United States of America and employs approximately 10 people. It has been publicly traded since 2023.